A study using a genetically engineered pancreatic cancer mouse model showed that cancer cells with a gain-of-function mutant p53 gene (GOF p53) promoted an aggressive CAF phenotype, resulting in an increased expression of contractile markers as compared to CAFs cultured with p53 null mutant cancer cells (p53 null) [43]. The gene discussed is TP53; the disease is pancreatic neoplasm.